Quest launches new product ‘DART’ to aid BPH patients
Kathmandu, March 7, 2017:
To help patients with the treatment of enlarged prostate resulting in dysfunctional urinary system, Quest Pharmaceuticals launched a new product named DART, today. Generically called Dutasteride, DART, relieves individuals suffering from Benign Prostate Hyperplasia (BPH).
A common ailment among men above 50 years of age, BPH, as per some reports, affects over 50% of the male population. Symptoms range from urinary irregularities affecting control, to urinary tract infections. Severe cases can lead to kidney damage.
“BPH is extremely common among senior citizen of our society, and our product DART offers a more effective alternative to treat BPH in Nepal, while improving the safety of patients.” said S.P.Verma, Director Marketing, Quest Pharmaceuticals P. Ltd.
DART is available in 0.5 mg tablet at all major medical stores in the country, with circulation facilitated by our 100+ distribution partners.